Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients (Publication with Expression of Concern)
Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients (Publication with Expression of Concern)
复制标题
DOI：
10.1007/s11255-016-1399-4
复制
发表时间：
2016-11-01
影响因子：
2
通讯作者：
Esmaillzadeh, Ahmad
中科院分区：
文献类型：
--
作者：
Asemi, Zatollah;Soleimani, Alireza;Esmaillzadeh, Ahmad
目的探讨ω-3脂肪酸和α-生育酚联合补充对慢性血液透析（HD）患者营养不良-炎症评分（MIS）、炎症标志物和氧化应激的影响。患者被随机分配到四组，接受：（1）1250 mg/天欧米茄-3脂肪酸（含600 mg EPA和300 mg DHA）+ α-生育酚安慰剂（n = 30）;（2）400 IU/天α-生育酚+欧米茄-3脂肪酸安慰剂（n = 30）;（3）1250 mg ω-3脂肪酸/天+400IU/天α-生育酚（n = 30）;（4）ω-3脂肪酸安慰剂+ α-生育酚安慰剂组（n = 30）干预12周。与安慰剂组相比，单独的ω-3脂肪酸以及ω-3脂肪酸和α-生育酚的组合经历了MIS的显著改善;但是，在此情况下，单个omega-3脂肪酸的改善要大得多，（-1.4 +/-1.4）和ω-3脂肪和α-生育酚组合组（-1.1 +/-2.3）与α-生育酚单独组（-0.5 +/-1.7，P = 0.004）相比。此外，单独和联合使用omega-3脂肪和α-生育酚的干预导致血浆一氧化氮（NO）显著增加。（联合组：+17.6 +/- 29.3; α-生育酚：+43.1 +/- 36.3; ω-3脂肪：+31.0 +/- 40.0;安慰剂：-0.5 +/- 18.5 μ mol/ L，P < 0.001）和总抗氧化能力（TAC）（分别为+64.9 +/- 113.6、+53.0 +/- 144.6、+57.6 +/- 157.8和-69.9 +/- 215.1 mmol/ L，P = 0.004）水平。血浆NO和TAC水平。未来需要更长时间的干预研究来证实我们研究结果的有效性。
Objective The current study was carried out to assess the effects of omega-3 fatty acid and alpha-tocopherol co-supplementation on malnutrition-inflammation score (MIS), biomarkers of inflammation and oxidative stress in chronic hemodialysis (HD) patients.Methods In a randomized double-blind placebo-controlled clinical trial, 120 patients with chronic HD were included. Patients were randomly allocated into four groups to receive: (1) 1250 mg/ day omega-3 fatty acid containing 600 mg EPA and 300 mg DHA + alpha-tocopherol placebo (n = 30); (2) 400 IU/ day alpha-tocopherol + omega-3 fatty acids placebo (n = 30); (3) 1250 mg omega-3 fatty acids/ day + 400 IU/ day alpha-tocopherol (n = 30); and (4) omega-3 fatty acids placebo + alpha-tocopherol placebo (n = 30) for 12 weeks.Results After 12 weeks of intervention, all three groups of alpha-tocopherol only, individual omega-3 fatty acids, and combined omega-3 fatty acids and alpha-tocopherol experienced a significant improvements in MIS compared with the placebo group; however, improvements were much greater in the individual omega-3 fats (-1.4 +/- 1.4) and combined omega-3 fats and alpha-tocopherol (-1.1 +/- 2.3) groups compared with alpha-tocopherol group alone (-0.5 +/- 1.7, P = 0.004). Furthermore, both individual and combined intervention with omega-3 fats and alpha-tocopherol led to a significant increase in plasma nitric oxide (NO) (combined group: +17.6 +/- 29.3; alpha-tocopherol: +43.1 +/- 36.3; omega-3 fats: +31.0 +/- 40.0; and placebo: -0.5 +/- 18.5 mu mol/ L, respectively, P < 0.001) and total antioxidant capacity (TAC) (+64.9 +/- 113.6, +53.0 +/- 144.6, +57.6 +/- 157.8 and -69.9 +/- 215.1 mmol/ L, respectively, P = 0.004) levels.Conclusion Overall, omega-3 fatty acids and alpha-tocopherol co-supplementation for 12 weeks among HD patients improved MIS, plasma NO and TAC levels. Future studies with longer duration of the intervention are needed to confirm the validity of our findings.